NRx Pharmaceuticals, Inc. (NRXP) 

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP). The investigation concerns whether NRx and certain of its officers and/or directors have violated federal securities laws.

 

On November 4, 2021, NRx issued a press release “announc[ing] that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for ZYESAMI® (aviptadil).  The FDA stated that it was unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the medicine and the known and potential risks of ZYESAMI in patients suffering from Critical COVID-19 with respiratory failure.”  On this news, NRx’s stock price fell sharply during intraday trading on November 5, 2021.

 

If you are aware of any facts relating to this investigation, or purchased NRx shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.